ACR2022 - Day 1.1

Best of PsA on Day 1
Dr. Rachel Tate discusses the best PSA data presented Saturday, November 12, 2002 at ACR22 Convergence. 
Abstract 0387: Sleep Quality in Patients with Psoriatic Arthritis and Its Relationship with Activity and Comorbidity
Abstract 0377: Differences in Early-onset vs. Late-onset Psoriatic Arthritis: Data from the RESPONDIA and REGISPONSER Studies

Can computers tell the difference between RA & PsA?
Dr. David Liew discusses Abstract 0242 presented at ACR22 in Philadelphia, PA.
Abstract 0242: Neural Networks for Distinguishing Rheumatoid Arthritis from Psoriatic Arthritis by Using Magnetic Resonance Imaging

Can you use the BASDAI in Pregnancy?
Dr. Eric Dein discusses abstract 0374 presented at ACR22 Convergence in Philadelphia, PA.
Abstract 0374: The BASDAI Index During Pregnancy

Drs Tate and Worthing What's going on on the Hill
Session # 12S119.

Effect of voclosporin in class V lupus nephritis
Dr. Yusof discusses abstract 0355 presented at ACR22 Convergence in Philadelphia, PA. 
Abstract 0355: Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results from the AURORA 2 Continuation Study

Microbiome and AxSPA
Dr. Akhil Sood discusses abstract 1162 presented at ACR22 Convergence in Philadelphia, PA. 
Abstract 1162: Improvement of Gut Microbiota Dysbiosis in Patients with Axial Spondyloarthritis After One Year of Biological Treatment

Opioids and Health Care Utilization in PsA and AS
Dr Aurelie Najm  discusses Abstract 0402 presented at ACR22 Convergence in Philadelphia, PA.
Abstract 0402: Opioid Use and Healthcare Utilization in Adults with PsA and AS

Switching Between JAK Inhibiters in RA
Dr. Janet Pope discusses abstract 0274 presented at ACR22 Convergence in Philadelphia, PA. 
Abstract 0274: Real-world Utilisation and Switching Between Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis in the Australian OPAL Dataset

Treatment Choices and Mortality in RA ILd 2
Dr. Julian Segen, Philadelphia
Dr. Bryant England, Philadelphia

Upadacitinib vs  Adalimumab in PsA using RAPID3
Dr. Catherine Sims discusses abstract 0192 presented at ACR22 Convergence. 
0192: Upadacitinib versus Adalimumab on Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Psoriatic Arthritis